http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001506642-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 1997-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001506642-A |
| titleOfInvention | Use of 2- (2-morpholinophenyl) guanidine derivatives for the treatment of diabetic complications |
| abstract | (57) The formula (I) wherein R 1 and R 2 are each independently H or methyl. Wherein R 1 and R 2 are each independently H or methyl, or a pharmaceutically acceptable salt thereof (eg, 1,1-dimethyl-2- (2-morpholinophenyl) Guanidine fumarate) is used to inhibit the formation of advanced glycosylation end products and is used to treat the long-term complications associated with diabetes, such as atherosclerosis, renal damage, neuropathy and retinopathy. // used for prevention. |
| priorityDate | 1996-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 106.